12:00 AM
 | 
Jan 28, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Iluvien regulatory update

The U.K.'s NICE issued final guidance recommending against the use of Iluvien fluocinolone acetonide intravitreal implant from Alimera to treat chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies - its approved indication. The decision is in line with a final appraisal determination (FAD) issued last November, in...

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >